160 related articles for article (PubMed ID: 6396766)
41. Vincristine, doxorubicin and mitomycin (VAM) in patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate and fluorouracil (CMF). A clinical trial of the Piedmont Oncology Association (POA).
Shipp SK; Muss HB; Westrick MA; Cooper MR; Jackson DV; Richards FC; White DR; Stuart JJ; Christian RM; Ramseur W
Cancer Chemother Pharmacol; 1983; 11(2):130-3. PubMed ID: 6354509
[TBL] [Abstract][Full Text] [Related]
42. Adjuvant systemic therapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients.
Mouridsen HT; Rose C; Brincker H; Thorpe SM; Rank F; Fischerman K; Andersen KW
Recent Results Cancer Res; 1984; 96():117-28. PubMed ID: 6396765
[No Abstract] [Full Text] [Related]
43. Adjuvant chemoimmunotherapy with LMF + BCG in node-negative and node-positive breast cancer: 8 year results.
Senn HJ; Jungi WF; Amgwerd R; Hochuli E; Ammann J; Engelhart G; Heinz C; Wick A; Enderlin F; Creux G
Recent Results Cancer Res; 1984; 96():90-101. PubMed ID: 6528092
[No Abstract] [Full Text] [Related]
44. Evolving concepts in the systemic adjuvant treatment of breast cancer.
Bonadonna G
Cancer Res; 1992 Apr; 52(8):2127-37. PubMed ID: 1559216
[No Abstract] [Full Text] [Related]
45. [Chemotherapy of metastasizing breast cancer].
Wascher H
Wien Med Wochenschr; 1985 Dec; 135(23-24):590-4. PubMed ID: 3841627
[TBL] [Abstract][Full Text] [Related]
46. Adjuvant chemotherapy in postmenopausal women: results of sequential noncross-resistant regimens.
Brambilla C; Rossi A; Valagussa P; Bonadonna G
World J Surg; 1985 Oct; 9(5):728-37. PubMed ID: 3840630
[No Abstract] [Full Text] [Related]
47. Therapeutic strategies in inflammatory breast carcinoma based on prognostic factors.
Rouëssé J; Friedman S; Mouriesse H; Sarrazin D; Spielmann M
Breast Cancer Res Treat; 1990 Jul; 16(1):15-22. PubMed ID: 2207344
[TBL] [Abstract][Full Text] [Related]
48. Adjuvant therapy of breast cancer: the Southwest Oncology Group experience.
Knight WA; Rivkin SE; Glucksberg H; Foulkes MA; Costanzi JJ; Stephens RL; Athens JW; O'Bryan RM
Breast Cancer Res Treat; 1983; 3 Suppl():S27-33. PubMed ID: 6367857
[TBL] [Abstract][Full Text] [Related]
49. Adjuvant chemotherapy with cyclophosphamide methotrexate and 5-fluorouracil (CMF) in stage II breast cancer in Indian patients.
Shetty PA; Sarda PK; Majumdar AT; Pai VR; Shinde SR; D'Souza LJ; Pinto JM; Jussawalla DJ
Indian J Cancer; 1985 Sep; 22(3):239-44. PubMed ID: 3843327
[No Abstract] [Full Text] [Related]
50. Multiple drug intensification after cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) induction in metastatic breast cancer: a Southeastern Cancer Study Group phase II trial.
Vogel CL; Raney M; Carpenter J
Cancer Treat Rep; 1987 Dec; 71(12):1271-3. PubMed ID: 3690536
[No Abstract] [Full Text] [Related]
51. Significant survival benefit of node-negative breast cancer patients treated with adjuvant chemotherapy: seven-year results.
Jakesz R; Reiner G; Schemper M; Reiner A; Blijham G; Rainer H; Dittrich D; Spona J; Schutte B; Reynders M
Recent Results Cancer Res; 1989; 115():180-5. PubMed ID: 2696031
[No Abstract] [Full Text] [Related]
52. The role of post-operative radiotherapy in the treatment of operable breast cancer.
Beadle GF; Harris JR
Breast Cancer Res Treat; 1984; 4(3):159-68. PubMed ID: 6386074
[TBL] [Abstract][Full Text] [Related]
53. Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer?
Esteva FJ; Hortobagyi GN
J Natl Cancer Inst; 2008 Apr; 100(8):521-3. PubMed ID: 18398093
[No Abstract] [Full Text] [Related]
54. Salvage treatments in relapsing resectable breast cancer.
Valagussa P; Brambilla C; Zambetti M; Bonadonna G
Recent Results Cancer Res; 1989; 115():69-76. PubMed ID: 2696043
[No Abstract] [Full Text] [Related]
55. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
Weiss RB; Woolf SH; Demakos E; Holland JF; Berry DA; Falkson G; Cirrincione CT; Robbins A; Bothun S; Henderson IC; Norton L;
J Clin Oncol; 2003 May; 21(9):1825-35. PubMed ID: 12721260
[TBL] [Abstract][Full Text] [Related]
56. Ludwig Breast Cancer trials LBCS III and IV: adjuvant endocrine treatment in postmenopausal patients.
Goldhirsch A
Recent Results Cancer Res; 1984; 96():204-9. PubMed ID: 6549355
[No Abstract] [Full Text] [Related]
57. Cancer and Leukemia Group B adjuvant chemotherapy trials in postmastectomy breast cancer patients.
Wood WC
Breast Cancer Res Treat; 1983; 3 Suppl():S39-43. PubMed ID: 6367859
[TBL] [Abstract][Full Text] [Related]
58. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.
Taghian A; Jeong JH; Mamounas E; Anderson S; Bryant J; Deutsch M; Wolmark N
J Clin Oncol; 2004 Nov; 22(21):4247-54. PubMed ID: 15452182
[TBL] [Abstract][Full Text] [Related]
59. Role of chemotherapy in acute breast cancer. Analysis of 41 cases.
Calderoli H; de Manzini N; Keiling R
Int Surg; 1988; 73(2):112-5. PubMed ID: 3397256
[TBL] [Abstract][Full Text] [Related]
60. Neoadjuvant chemotherapy in the conservative management of breast cancer: a study of 252 patients.
Jacquillat C; Weil M; Auclerc G; Auclerc MF; Khayat D; Baillet F
Recent Results Cancer Res; 1989; 115():36-42. PubMed ID: 2516351
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
